Single-Arm Clinical Study of EZH2i in Combination With Glofitamab + GemOx in Patients With Relapsed/ Refractory DLBCL

NCT07643805 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

46

Enrollment

OTHER

Sponsor class

Conditions

DLBCL

Interventions

DRUG: EZH2i+GLofit-GemOx

Sponsor

The First Affiliated Hospital with Nanjing Medical University